Prescription drug · BLA
Lerochol (Lerodalcibep-liga) NDC 84685-300
Lerodalcibep 300 mg/1.2mL · Injection, Solution · Subcutaneous · LIB Therapeutics, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 84685-300-01 | 84685030001 | 1 SYRINGE in 1 CARTON (84685-300-01) / 1.2 mL in 1 SYRINGEMarketed from Mar 31, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Lerochol
- Generic name (nonproprietary)
- lerodalcibep-liga
- Active ingredients
- Lerodalcibep — 300 mg/1.2mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- LIB Therapeutics, Inc.NDC labeler code 84685
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761427
- Marketing start
- Listing expires
- Identifiers
- Product ID 84685-300_5d5134f8-4b97-4e65-a18a-654744214b53SPL ID 5d5134f8-4b97-4e65-a18a-654744214b53SPL set ID 422f8b04-6ce8-4e64-a0a9-0ccc9a4a5860RxCUI 2729467, 2729474UNII 1PHP3QG5PZ
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N484685030001followed by a unit qualifier and the quantityPackage 84685-0300-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
LEROCHOL TM is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). LEROCHOL is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated as an adjunct to diet and exercise: to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 84685-300
- What is NDC 84685-300?
- 84685-300 is the product NDC for Lerochol (lerodalcibep-liga), Lerodalcibep 300 mg/1.2mL injection, solution, listed with the FDA by LIB Therapeutics, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Lerochol (Lerodalcibep-liga).
- What is the active ingredient?
- Lerodalcibep.
- Who is the labeler?
- LIB Therapeutics, Inc., NDC labeler code 84685. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Lerochol?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.